1Bayes-Genis A,De Antonio M,Galan A,et al. Combined use of high-sensitivity ST2 and NT-proBNP to improve the prediction of death in heart failure[J]. Eur J Heart Fail,2012,4(1) : 32-38.
2Manzano-Fernandez S, Mueller T, Pascual-Figal D,et al. Use- fulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely deeompen- sated heart failure relative to left ventricular ejection fraction[J1. Am J Cardiol, 2011,1 07 (2) : 259-267.
4Miller AM,Hew FY. The IL-33/ST2 pathway-A new therapeutic target in cardiovascular disease [J]. Pharmacol Ther, 2011,131(2): 179-186.
5Karolina WS, Tadeusz P, Sakowic A, et al. Soluble ST2 protein in chronic heart failure is independent of traditional factors [J]. Arch Med Sci ,2013,9( 1 ) : 21-26.
6Wang YC ,Yu CC,Chiu FC ,et al. Soluble ST2 as a biomarker for detecting stable heart failure with a normal ejection fraction in hypertensive patients[J]. J Card Fail,2013,19(3) : 163-168.
7Aldous SJ,Richards AM,Troughton R,et al. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain [J]. J Card Fail,2012,18(4) :304-310.
8Dieplinger B,Gegenhuber A,Haltmayer M,et al. Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath [J].Heart,2009,95 (18): 1508-1513.
1Tominaga S.A putative protein of a growth specific cDNA fromBALB/c-3T3 cells is highly similar to the extracellular portion ofmouse interleukin 1 receptor[J].FEBS Lett,1989,258:301-304.
2Sanada S,Hakuno D,Higgins L J,Schreiter E R,McKenzie A N,Lee R T.IL-33 and ST2 comprise a critical biomechanically in- duced and cardioprotective signaling system[J].J Clin Invest,2007,117:1538-1549.
3Bartunek J,Delrue L,Van Durme F,Muller O,Casselman F,DeWiest B,et al.Nonmyocardial production of ST2 protein in humanhypertrophy and failure is related to diastolic load[J].J Am CollCardiol,2008,52:2166-2174.
4Rehman S U,Mueller T,Januzzi J L Jr.Characteristics of the novelinterleukin family biomarker ST2 in patients with acute heart fail-ure[J].J Am Coll Cardiol,2008,52:1458-1465.
5Januzzi J L Jr,Peacock W F,Maisel A S,Chae C U,Jesse R L,Baggish A L,et al.Measurement of the interleukin family memberST2 in patients with acute dyspnea:results from the PRIDE(Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emer- gency Department)study[J].J Am Coll Cardiol,2007,50:607-613.
6Braunwald E.Biomarkers in heart failure[J].N Engl J Med,2008,358:2148-2159.
7Krauser D G,Lloyd-Jones D M,Chae C U,Cameron R,Anwarud-din S,Baggish A L,et al.Effect of body mass index on natriureticpeptide levels in patients with acute congestive heart failure:aProBNP Investigation of Dyspnea in the Emergency Department(PRIDE)substudy[J].Am Heart J,2005,149:744-750.
8Vasan R S,Sullivan L M,Roubenoff R,Dinarello C A,Harris T,Benjamin E J,et al.Inflammatory markers and risk of heart failurein elderly subjects without prior myocardial infarction:the Fram-ingham Heart Study[J].Circulation,2003,107:1486-1491.
9Anand I S,Latini R,Florea V G,Kuskowski M A,Rector T,MassonS,et al.C-reactive protein in heart failure:prognostic value andthe effect of valsartan[J].Circulation,2005,112:1428-1434.
10Venugopal S K,Devaraj S,Jialal I.Effect of C-reactive protein onvascular cells:evidence for a proinflammatory,proatherogenic role[J].Curr Opin Nephrol Hypertens,2005,14:33-37.
